Heart of Type 2

You set targets for A1C, LDL-C, and blood pressure. But are your patients with T2D still at risk?

The comorbidities accompanying type 2 diabetes lead to a myriad of long-term complications, with high risk of developing cardiovascular disease, as well as microvascular complications.1

You set targets for A1C, LDL-C, and blood pressure. But are your patients with T2D still at risk?

The comorbidities accompanying type 2 diabetes lead to a myriad of long-term complications, with high risk of developing cardiovascular disease, as well as microvascular complications.1

Patients with diabetes have excess cardiovascular risk

Link between T2D and CVD

Compared with patients without diabetes, patients with diabetes have an excess cardiovascular risk. In fact, they have a 2- to 6-times higher risk of mortality from CV events.2,3

People with diabetes are also at increased risk of atherosclerotic CVD

CV risk and increased morbidity

People with diabetes are also at increased risk of atherosclerotic CVD, including acute coronary syndromes, myocardial infarctions, angina, stroke, and peripheral artery disease.1

14% - 18% still experience a CV event

Residual CV risk

Even treatment with high-dose statins leaves residual CV risk in patients with diabetes4

  • Patients with diabetes and CHD treated with high-dose statin had a 25% reduction in major CV events4
  • Still, 14% to 18% of patients experienced an event, even with therapy4
     

Professional resources

Hear from your peers and access additional resources such as diabetes treatment guidelines.

CV=cardiovascular; CVD=cardiovascular disease; T2D=type 2 diabetes; CHD=coronary heart disease

 

References:

  1. American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017;40(Suppl1):S1-S135.
  2. Fitch KV, Blumen HE, Engel T. Cardiovascular event incidence and cost in type 2 diabetes: a commercial and Medicare claim based actuarial analysis. http://us.milliman.com/uploadedFiles/insight/2016/Cardiovascular-Event-Rate-and%20Cost-Diabetes.pdf. Published November 2016. Accessed February 1, 2017.
  3. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012;60(24):e44-e164.  
  4. Shepherd J, Barter P, Carmea R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. Diabetes Care. 2006;29:1220-1226.

CV=cardiovascular; CVD=cardiovascular disease; T2D=type 2 diabetes; CHD=coronary heart disease

 

References:

  1. American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017;40(Suppl1):S1-S135.
  2. Fitch KV, Blumen HE, Engel T. Cardiovascular event incidence and cost in type 2 diabetes: a commercial and Medicare claim based actuarial analysis. http://us.milliman.com/uploadedFiles/insight/
    2016/Cardiovascular-Event-Rate-and%20Cost-Diabetes.pdf. Published November 2016. Accessed February 1, 2017.
  3. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012;60(24):e44-e164.  
  4. Shepherd J, Barter P, Carmea R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. Diabetes Care. 2006;29:1220-1226.